about
Successful palliative approach with high-intensity focused ultrasound in a patient with metastatic anaplastic pancreatic carcinoma: a case report.Hindbrain hernia headache and syncope in type I Arnold-Chiari malformation.Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO).Hepatic intra-arterial chemotherapy using a percutaneous catheter in pretreated patients with metastatic colorectal carcinoma.Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study.Hepatic intra-arterial chemotherapy in patients with advanced primary liver tumours.Real-world study of everolimus in advanced progressive neuroendocrine tumors.Natural history of malignant bone disease in hepatocellular carcinoma: final results of a multicenter bone metastasis survey.Italian Association of Clinical Endocrinologists (AME) position statement: a stepwise clinical approach to the diagnosis of gastroenteropancreatic neuroendocrine neoplasms.Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24-25 June 2014, Milan.Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the XELBEVOCT studyNeuroendocrine tumour arising inside a retro-rectal tailgut cyst: report of two cases and a review of the literature.Institutional guidelines and ongoing studies in management of liver tumours: the experience of the European Institute of Oncology.Human papillomavirus in anal squamous cell carcinoma: an angel rather than a devil?Docetaxel in advanced gastric cancer--review of the main clinical trials.Pregnant with metastatic neuroendocrine tumour of the ovary: what now?Surgical outcomes for colon and rectal cancer over a decade: results from a consecutive monocentric experience in 902 unselected patientsA Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease managementA Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours.Dual modulation of MCL-1 and mTOR determines the response to sunitinib.ENETS consensus guidelines for the management of peritoneal carcinomatosis from neuroendocrine tumors.Chemotherapy in pancreatic adenocarcinoma.Adjuvant colon cancer chemotherapy: where we are and where we'll go.Molecularly targeted endocrine therapies for breast cancer.Chemotherapy in gastroenteropancreatic (GEP) neuroendocrine carcinomas (NEC): a critical view.Extrapulmonary neuroendocrine small and large cell carcinomas: a review of controversial diagnostic and therapeutic issues.RAF signaling in neuroendocrine neoplasms: from bench to bedside.Temozolomide in Advanced Neuroendocrine Neoplasms: Pharmacological and Clinical Aspects.Dual inhibition of mTOR pathway and VEGF signalling in neuroendocrine neoplasms: from bench to bedside.Systemic therapy beyond first-line in advanced gastric cancer: An overview of the main randomized clinical trials.Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors.Metronomic and metronomic-like therapies in neuroendocrine tumors - Rationale and clinical perspectives.Assessing the role of primary tumour resection in patients with synchronous unresectable liver metastases from pancreatic neuroendocrine tumour of the body and tail. A propensity score survival evaluation.Grading lung neuroendocrine tumors: Controversies in search of a solution.Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications.Treatments for colorectal liver metastases: A new focus on a familiar concept.HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?Critical focus on mechanisms of resistance and toxicity of m-TOR inhibitors in pancreatic neuroendocrine tumors.Resection of colorectal liver metastases following neoadjuvant chemotherapy.
P50
Q30383858-71E22568-7E7B-4984-AAEC-B7981CACE7C7Q33174155-22F4B588-2BB7-45AE-BC55-B6CC6FA11753Q33332444-FE4E02D1-B86A-4BEC-A35D-BDECC89974FBQ33359701-01F66C63-4E55-4353-B636-EA89A9BFD38FQ33397018-1C683755-8379-4809-A831-89D3A94CFFD4Q33404756-F65AA24C-639A-4108-8183-1C3B73D25695Q33417013-8D60CE41-529B-468D-B0BA-4B426BC3351DQ34109952-31F5B00B-1F25-42D4-B28B-905B3E98806EQ34157385-4828FE62-605B-4669-96E5-33D439C5F5D9Q34173001-F5FEC8BD-5D6C-4365-A0C9-5B1118CE3FF5Q35120723-358DAEB9-BC52-4635-AAA4-BC8B362151FEQ35572776-CB734F84-48AA-4C53-9109-5C88376FED29Q35602256-6E6C10F1-B67E-4ED5-AD42-6137DB1EA272Q35605619-B3A0EC3B-7817-4B4A-875B-4CEF4CD0F4EAQ35613504-81BAFC00-D590-478F-9D68-DA3AED897380Q35740653-3B13A51B-F931-41A8-BCDA-06E5B8200121Q35962604-E66D4336-3DD5-42E7-BC18-55D47B4D7C70Q37302087-AC75BF0D-3021-4361-A798-38CD5EDEC69FQ37361194-EF04CAA8-6870-464D-A5C0-ACD96E674F61Q37544978-9931657E-BAA1-4733-BE14-DC68F5AA46DCQ37737927-06EE89FA-75C1-4BD0-85EE-D3C82AB68A3AQ37760186-7C9ECD7D-240A-45C5-AA72-6A8C5FE6F0D2Q37815610-A1F8B780-DC27-482E-B15F-DA3CCDFF9891Q37815616-51DF2891-5BEF-4393-B4A3-D51CBF10C82EQ38028178-BC5175AC-7771-4ABB-9E45-2CC4F5405982Q38117465-FB2C76A7-DD94-4FBD-A582-7EBFACC1D8F9Q38226707-A68E3A5C-3BD4-4D63-8444-E6244E7FF774Q38449565-009AA567-1D3F-4DC2-BD89-295E5D7C9CE3Q38542778-0245820D-442E-4082-AF8A-D21664A70ACAQ38677283-AE3C99BB-EE40-4D2C-AF02-9F313C6182B0Q38679359-70EA7EA3-2B71-4A49-8F44-6855B9D10895Q38716228-7F649551-9088-43A9-8156-F0EBB09238B2Q38743527-47D73657-D68E-4DE5-A7F7-1D15550DD6CCQ38811556-98064070-E6E2-4152-BF55-D473063763A5Q38954551-6C6EE128-670C-45FC-AB17-28A058851616Q38956214-84A93B9E-FE6C-4301-BB47-3CAB35155093Q39033363-B684A3EB-5745-4A54-B51C-C2627877EC9EQ39040859-E760658A-3591-4FDE-B0C0-F50D8A6C808BQ39324669-170CF8E7-F8E9-422D-B96C-2A1118C26D32Q39369342-90204F5E-BB4E-4B01-BE13-EFC48EE191C6
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Nicola Fazio
@ast
Nicola Fazio
@en
Nicola Fazio
@es
Nicola Fazio
@nl
Nicola Fazio
@pt
Nicola Fazio
@sl
type
label
Nicola Fazio
@ast
Nicola Fazio
@en
Nicola Fazio
@es
Nicola Fazio
@nl
Nicola Fazio
@pt
Nicola Fazio
@sl
prefLabel
Nicola Fazio
@ast
Nicola Fazio
@en
Nicola Fazio
@es
Nicola Fazio
@nl
Nicola Fazio
@pt
Nicola Fazio
@sl
P106
P21
P31
P496
0000-0001-6869-0704